Does Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands?
news via Technology - Investor's Business Daily
Top-notch biotech stock Neurocrine surged Tuesday after analysts suggested the company's depression treatment could rival ketamine. The post Does Neurocrine, The No. 1 Biotech Stock, Have The Next Ketamine On Its Hands? appeared first on Investor's Business Daily....
READ FULL ARTICLE »
Become a member to take advantage of more features, like commenting and voting.
Register or sign in today!